Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma.

BMC Cancer

Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

Published: September 2009

Background: Cancer of the esophagus is a deadly malignancy, and development of biomarkers that predict survival is an urgent need. The apoptotic pathways have been hypothesized as important in progression of esophageal squamous cell carcinoma (ESCC). We investigated a panel of proteins that regulate apoptosis as candidate of biomarkers of prognosis in ESCC.

Methods: Tissue microarray (TMA) including 313 surgically-resected cases of ESCC specimens was built for immunohistochemical interrogation. We evaluated seven genes in the FasL-Fas apoptotic pathway - FasL, Fas, FAS-associated death domain protein (FADD), phosphorylated-FADD, and caspase 8 and 10, and the antiapoptotic protein bcl-2. We studied pathway integrity and relations to risk and clinical factors, and determined the prognostic significance of each marker.

Results: Five markers showed strong inter-marker correlations (r > or = 0.28, p < 0.001), including FasL, Fas, FADD, and caspases 8 and 10. FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases. Multivariate-adjusted proportional hazard regression models showed no association between protein expression and risk of death for any of the seven markers examined.

Conclusion: Individual biomarkers in the apoptosis pathway do not appear to predict survival of patients with ESCC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745431PMC
http://dx.doi.org/10.1186/1471-2407-9-310DOI Listing

Publication Analysis

Top Keywords

biomarkers apoptosis
8
esophageal squamous
8
squamous cell
8
cell carcinoma
8
predict survival
8
fasl fas
8
clinical factors
8
biomarkers
4
survival
4
apoptosis survival
4

Similar Publications

Nowadays, chemotherapy and immunotherapy remain the major treatment strategies for Triple-Negative Breast Cancer (TNBC). Identifying biomarkers to pre-select and subclassify TNBC patients with distinct chemotherapy responses is essential. In the current study, we performed an unbiased Reverse Phase Protein Array (RPPA) on TNBC cells treated with chemotherapy compounds and found a leading significant increase of phosphor-AURKA/B/C, AURKA, AURKB, and PLK1, which fall into the mitotic kinase group.

View Article and Find Full Text PDF

Human cancer cells xenografts to assess the efficacy of granulysin-based therapeutics.

Methods Cell Biol

January 2025

Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, Zaragoza, Spain. Electronic address:

9-kDa Granulysin is a protein present in the granules of human activated cytotoxic T lymphocytes and natural killer cells. It has been shown to exert cytolytic activity against a wide variety of microbes: bacteria, fungi, yeast and protozoa. Recombinant isolated granulysin is also capable of inducing tumor cell death, so it could be used as an anti-tumor therapy.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers and is associated with poor survival. Formosanin C (FC) is a diosgenin glycoside extracted from Paris polyphylla. Therapeutic effects of FC against HCC malignancies remain unclear.

View Article and Find Full Text PDF

Bisphenol A (BPA) is a hazardous endocrine disruptor released into the environment during the production of certain plastics used for covering of food and beverage cans. In this work, we examined the protective benefits of selenium (Se) against intestinal damage induced by BPA in male rats. Rats were distributed randomly into four groups.

View Article and Find Full Text PDF

Exploring the Chemopreventive Potential of Methanolic Extract in Colorectal Cancer Induced by Azoxymethane in Mice.

Pharmaceuticals (Basel)

December 2024

Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.

Colorectal cancer (CRC) remains a major global health burden, necessitating innovative preventive approaches. (), known for its extensive pharmacological properties, has shown potential in cancer therapy. This study investigates the chemopreventive efficacy of methanolic extract of (MEA) in an azoxymethane (AOM)-induced murine model of CRC, with a focus on its antioxidant, biomarker modulation, and pro-apoptotic activities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!